Merck/ModernaModerna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection
See how Big Pharma can fly through the approval process while everyone else gets pushed back towards the end of the bus. The FDA is corrupt to the bone. I hope Theralase can buck the trend. Fingers cross.